bioRxiv Science⌕ Search

bioRxiv · 10.64898/2026.11.02.763436

ANABOLIC FAILURE, NOT CATABOLIC ACTIVATION, UNDERLIES GLYCOGEN DEPLETION IN CERVICAL CARCINOGENESIS: A MULTI-COHORT TRANSCRIPTOMIC ANALYSIS

Abstract

Abstract Background. Cervical epithelium loses its glycogen as disease grade rises, an observation old enough to underpin iodine-based visual screening, but which arm of glycogen metabolism accounts for the loss has not been established. The expectation from cancer metabolism is catabolic: that stored glycogen is mobilized and glycolysis activated. Methods. We analyzed 238 specimens from four publicly available cohorts across three sample types: 128 laser-capture-microdissected epithelial samples, 35 bulk-tissue samples, and 75 exfoliated cytology samples in two sets (44 and 31; GSE27678). We prespecified a 33-gene panel comprising four modules: glycogen synthesis, glycogen degradation, glycolysis, and squamous differentiation. For each specimen, we calculated module scores using single-sample gene set enrichment. Differential expression was assessed with limma, pathway enrichment with fgsea, and classification performance with bootstrap confidence intervals for ROC curves. We documented all analytical decisions and their rationale. Results. Synthesis and differentiation fell with grade in all four cohorts, while degradation and glycolysis stayed at their normal-tissue baseline. All seven differentiation genes were reduced in carcinoma, and all seven occupied the top 5.1% of the ranked transcriptome, with CRNN the most down-regulated of 21,755 genes. Synthesis failed selectively, through GYS2 and PPP1R3C only, with the ubiquitous synthase GYS1 unchanged. The glycolytic module separated from normal epithelium at no grade (p 0.45 to 0.62), classified CIN3 or worse at an area under the curve of 0.569 with an interval spanning chance, and showed no enrichment in carcinoma. Synthesis separated from normal first, at CIN2, and differentiation at CIN3. The composite index tracked grade in the discovery cohort (Spearman rho 0.652, p 7.9e-17) but offered no discriminatory advantage over its differentiation component alone (0.832 against 0.832). Conclusions. Glycogen depletion in cervical carcinogenesis reflects failure of a tissue-restricted synthetic axis, GYS2 and PPP1R3C, within a collapsing squamous differentiation program, not catabolic activation. Measuring all four candidate mechanisms on one scale in the same specimen is what allows the catabolic explanation to be excluded rather than merely left untested. The pattern holds across two array chemistries and three specimen preparations, including the exfoliated cytology that screening already collects, and the synthesis and differentiation modules together are the molecular counterpart of what iodine staining reports. These are transcript-level findings and define no clinical threshold.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Ajayi, O. O., Odigie, E. B., Adesite, S. O., Erameh, T., Archibong, A. M., Eziagu, U. B.. 2026-11-03. ANABOLIC FAILURE, NOT CATABOLIC ACTIVATION, UNDERLIES GLYCOGEN DEPLETION IN CERVICAL CARCINOGENESIS: A MULTI-COHORT TRANSCRIPTOMIC ANALYSIS. https://doi.org/10.64898/2026.11.02.763436

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Tet2-Clonal Hematopoiesis Promotes Whereas Dnmt3a-CH Inhibits Breast Cancer Progression During Aging

Clonal hematopoiesis of indeterminate potential (CHIP) driven by somatic mutations in blood cells increases with age and is associated with adverse outcomes in cancer patients. How CHIP mutations influence solid tumor progression remains unclear. Using inducible murine models of Dnmt3a- or Tet2-mutant CHIP combined with orthotopic syngeneic breast cancer models, we demonstrate that upon aging Dnmt3a-mutant CHIP prevents whereas Tet2-mutant CHIP drives breast cancer progression. Dnmt3a-mutant immune infiltrates established interferon-mediated MHCIIhigh tumor-associated macrophages (TAMs) that supported cytotoxic CD8+ T cell-mediated tumor rejection. In contrast, Tet2-mutant TAMs exhibited an inflammatory, immunosuppressive phenotype characterized by increased IL-1 and CXCL2 production, reduced MHCII expression, and impaired T cell recruitment and activation. Therapeutic blockade of IL-1R1 or CXCR2 reduced tumor progression in aged Tet2-mutant CHIP mice and partially restored anti-tumor immunity. These findings establish that the effects of CHIP on cancer are mutation- and age-dependent and identify IL-1/CXCL2-driven inflammation as a therapeutic vulnerability of tumor-promoting Tet2-mutant CHIP.

cancer biology↗

Single Nucleus Profiling Reveals Rewired Tumor-Immune-Stromal Cell Communication in Plasmacytoid Urothelial Carcinoma

Plasmacytoid urothelial carcinoma (PUC) is an aggressive histologic subtype of bladder cancer associated with worse patient outcomes and therapeutic response compared to conventional urothelial carcinoma (CUC). While recent work has demonstrated metastatic lymph nodes from PUC tumors have an inflamed phenotype, how the tumor microenvironment (TME) and crosstalk between tumor, stromal, and immune cells in primary PUC bladder tumors differs from those in CUC remains poorly understood. The impact of these differences on response to immunotherapy is also unknown. To understand TME differences between CUC and PUC and their impact on cell signaling, we performed single nucleus RNA sequencing on PUC and CUC tumors, as well as Xenium spatial transcriptomics on a mixed CUC / PUC tumor. We identified increased signaling between PUC-enriched, CDH1-low urothelial cells, immunosuppressive lipid-associated macrophages, and SFRP2+/CTHRC1+ fibroblasts in PUC tumors compared to CUC. Spatial transcriptomics identified increased macrophage infiltration in PUC histology and colocalization of PUC tumor cells, immunosuppressive macrophages, and SFRP2+ fibroblasts. Taken together, this study delineates PUC architecture and demonstrates interplay CDH1-low tumor cells, EMT, and immunosuppressive macrophages, identifying possible therapeutic vulnerabilities in PUC.

cancer biology↗

The Phospholipase A2 Activity of Peroxiredoxin 6 Protects Hepatocarcinoma Cells Against Ferroptosis and Mitophagy Impairment

Peroxiredoxin 6 (PRDX6) is a moonlighting protein that plays a key role in regulating redox homeostasis and lipid metabolism through its unique dual peroxidase and calcium-independent phospholipase A2 (iPLA2) activities. Here, we generated a stable HepG2 cell line harboring a D140A mutation to selectively ablate iPLA2 activity, and we compared its phenotype with that of wild-type (WT) and PRDX6-knockout (KO) cells. D140A exhibited low ROS leves, similar to WT cells, confirming that oxidative stress is due to peroxidase deficiency. In contrast, D140A cells displayed higher lipid peroxidation than WT cells, though significantly lower than that of KO cells. Furthermore, the D140A mutant mirrored the KO phenotype regarding intracellular ferrous iron accumulation, impaired lipid droplet biogenesis, and the downregulation of the key ferroptosis regulator GPX4. Mechanistically, integrated proteomic, lipidomic, and enzymatic analyses revealed that a deficiency in iPLA2 activity of PRDX6 disrupted the release of key lipid species necessary for cell structure and signaling. Consequently, organelles involved in lipid synthesis and trafficking, such as peroxisomes, endoplasmic reticulum, mitochondria and lipid droplet, were affected. Specifically, we found that mitochondria exhibited a reduction in cristae and a diminished capacity for mitophagy and autophagy, which ultimately makes cells much more susceptible to erastin-induced ferroptotic cell death. Taken together, our findings demonstrate that PRDX6 iPLA2 activity uniquely coordinates organelle lipid homeostasis and mitophagy to protect cancer cells from ferroptotic cell death. Consequently, the use of iPLA2 inhibitors such as MJ33, which decreased PRDX6 iPLA2 activity to a level comparable to the mutant D140A, could represent a promising therapeutic strategy for inducing ferroptotic cell death in hepatocellular carcinoma.

cancer biology↗